

Ozarelix

Cat. No.:	HY-16375
CAS No.:	295350-45-7
Molecular Formula:	C ₇₂ H ₉₆ ClN ₁₇ O ₁₄
Molecular Weight:	1459.09
Target:	GnRH Receptor; Apoptosis
Pathway:	GPCR/G Protein; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Ozarelix (D-63153) is a GnRH antagonist. Ozarelix induces cell apoptosis and arrests cell in G2/M phase. Ozarelix can be used in the research of prostate cancer ^[1] .																	
In Vitro	<p>Ozarelix (0-20 ng/mL, 72 h) inhibits PC3 and DU145 cell proliferation^[1]. Ozarelix (0-20 ng/mL, 72 h) induces apoptosis in PC3 and DU145 cells^[1]. Ozarelix (20 ng/mL, 72 h) triggers caspase 8-dependent caspase 3 activation^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Proliferation Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>Serum-starved PC3 and DU145 cells</td> </tr> <tr> <td>Concentration:</td> <td>0, 5, 10, 20 ng/mL</td> </tr> <tr> <td>Incubation Time:</td> <td>0, 24, 48, 72, 96 h</td> </tr> <tr> <td>Result:</td> <td>Inhibited cell proliferation in a dose and time-dependent manner.</td> </tr> </table> <p>Western Blot Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>PC3 and DU145 cells</td> </tr> <tr> <td>Concentration:</td> <td>0, 5, 10, 20 ng/mL</td> </tr> <tr> <td>Incubation Time:</td> <td>72 h</td> </tr> <tr> <td>Result:</td> <td>Increased the levels of p21 and p27 both in PC3 and DU145 cells. Decreased levels of anti-apoptotic proteins such as Bcl2 and Bcl-XL. Upregulated Erk and p38MAPK activity.</td> </tr> </table>		Cell Line:	Serum-starved PC3 and DU145 cells	Concentration:	0, 5, 10, 20 ng/mL	Incubation Time:	0, 24, 48, 72, 96 h	Result:	Inhibited cell proliferation in a dose and time-dependent manner.	Cell Line:	PC3 and DU145 cells	Concentration:	0, 5, 10, 20 ng/mL	Incubation Time:	72 h	Result:	Increased the levels of p21 and p27 both in PC3 and DU145 cells. Decreased levels of anti-apoptotic proteins such as Bcl2 and Bcl-XL. Upregulated Erk and p38MAPK activity.
Cell Line:	Serum-starved PC3 and DU145 cells																	
Concentration:	0, 5, 10, 20 ng/mL																	
Incubation Time:	0, 24, 48, 72, 96 h																	
Result:	Inhibited cell proliferation in a dose and time-dependent manner.																	
Cell Line:	PC3 and DU145 cells																	
Concentration:	0, 5, 10, 20 ng/mL																	
Incubation Time:	72 h																	
Result:	Increased the levels of p21 and p27 both in PC3 and DU145 cells. Decreased levels of anti-apoptotic proteins such as Bcl2 and Bcl-XL. Upregulated Erk and p38MAPK activity.																	

REFERENCES

[1]. Festuccia C, et al. Ozarelix, a fourth generation GnRH antagonist, induces apoptosis in hormone refractory androgen receptor negative prostate cancer cells modulating expression and activity of death receptors. Prostate. 2010 Sep 1;70(12):1340-9.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA